Larotrectinib for children with newly diagnosed glioma with NTRK fusion
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 21 years old or younger when you enroll
- Have a newly diagnosed high-grade glioma (including DIPG) that tests positive for an NTRK fusion
- Not have received any prior chemotherapy (steroid medicines are usually allowed)
- Plan treatment that does NOT include craniospinal radiation (spine whole-area radiation) for most cases
- Have enough bone marrow and organ function (blood counts, kidney, liver), as measured by screening labs
- Be well enough to function (Lansky or Karnofsky score at or above the study cutoff)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests a drug called tovorafenib for children and young adults with certain types of brain tumors that have specific genetic changes. It is aimed at helping people who have just finished radiation therapy.
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.